Leading oncology experts and company management will discuss the Phase 3 OVATION 3 study, supporting

Imunon, Inc. (IMNN) Q2 2026 Earnings Call Transcript

Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.54) per share which beat the analyst consensus

Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's afte

Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well

IMUNON posts rapid patient enrollment in its Phase 3 OVATION 3 trial for ovarian cancer, targeting c

Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor

Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor power in

Preliminary data reinforces IMNN-001 immunotherapy's potential for success in the rapidly recruiting

Imunon Inc. (NASDAQ:IMNN) on Tuesday reported new preliminary findings from its ongoing Phase 2 mini

Imunon reports early Phase 2 data showing lower residual disease and higher ctDNA clearance with IMN

Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-mark

 On June 29, 2026, Jeffrey Church informed Imunon, Inc. (the "Company") of his intent to ret

IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated im

On track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing

LAWRENCEVILLE, N. J. , June 22, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-sta

Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.7

Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.7

Imunon, Inc. (IMNN) Q1 2026 Earnings Call Transcript

Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.84) per share which beat the analyst consensus

IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clin

LAWRENCEVILLE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage

Maxim Group analyst Jason McCarthy initiates coverage on Imunon (NASDAQ:IMNN) with a Buy rating a

Imunon, Inc. (IMNN) Q4 2025 Earnings Call Transcript

Imunon (NASDAQ:IMNN) reported quarterly losses of $(1.30) per share which missed the analyst consens

IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningf

https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_03252026_IMNN_Bautz.pdf

The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial ros

The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial ros

LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-sta

Imunon (NASDAQ: IMNN - Get Free Report) will likely be posting its Q4 2025 results before the market

Imunon (NASDAQ: IMNN - Get Free Report) and Pharma Mar (OTCMKTS:PHMMF - Get Free Report) are both me

Strategic Restructuring Eliminates Expenses Not Essential to the Phase 3 StudyKhursheed Anwer, Ph.D.

IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated im

Dear Valued Shareholders,2025, A Year of Momentum: Advancing Toward a Potential Breakthrough in Ovar

IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated im